EVEREST ORGANICS LTD.

Everest Organics Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter ended June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and applies to all directors, promoters, designated employees, and connected persons. The specific date for the board meeting to approve these results will be communicated separately.

Everest Organics Ltd appointed Mr. Narra Venkata Ramana as an Additional Director in the category of Independent Director for a term of five years, commencing May 29, 2026, subject to shareholder approval. He was also appointed as the Chairman of the Company. The Board Meeting, held on May 29, 2026, also approved the audited financial results for the quarter and year ended March 31, 2026, and reconstituted various board committees.

Everest Organics Ltd. announced the audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in their meeting held on May 29, 2026. Mr. Narra Venkata Ramana was appointed as an Additional Director in the category of Independent Director and as the Chairman of the Company, effective May 29, 2026, subject to shareholder approval. The board also approved the reconstitution of various committees.

Everest Organics Ltd's board meeting on May 29, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board also appointed Mr. Narra Venkata Ramana as an Additional Director (Independent) and Chairman, effective May 29, 2026, subject to shareholder approval. Additionally, the board reconstituted various committees in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.

Everest Organics Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026. The board will also review the draft report from the statutory auditors for the same financial year. The trading window closure period, which commenced on April 1, 2026, will remain in effect until 48 hours after the declaration of the financial results.

Everest Organics Ltd has announced the closure of its trading window for dealing in the company's securities by its designated persons and their immediate relatives. The closure is in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct. The trading window will remain closed from Wednesday, April 01, 2026, till 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ending March 31, 2026. The date of the Board Meeting for consideration and approval of the Audited Financial Results will be intimated to the Stock Exchange in due course.

Everest Organics Ltd. has disclosed reasons for the delay in submitting its unaudited financial results for the quarter ended December 31, 2025. The Board Meeting, which started on February 14, 2026, at 8:45 PM and concluded on February 15, 2026, at 1:00 AM, required additional information before finalization. This led to the inability to submit the financial results within the 45-day period as per Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the company uploaded the results on the BSE Listing Portal immediately after the Board Meeting, and the delay in submitting the explanation was unintentional. The company regrets the oversight and assures the Exchange of timely submission of all required disclosures in the future.

Everest Organics Limited has submitted its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a sales turnover of Rs 5026.85 Lakhs for the quarter, with domestic sales at Rs. 3970.75 Lakhs and export sales at Rs. 1056.10 Lakhs. The company operates in one reportable business segment: Active Pharmaceutical Ingredients (APIs) and Intermediates. There were 2,63,157 Equity Share Warrants outstanding on 31.12.2025. The financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors.

Everest Organics Limited has submitted its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's revenue for Q3 2025 was Rs. 5026.85 Lakhs, with domestic sales of Rs. 3970.75 Lakhs and export sales of Rs. 1056.10 Lakhs. The company operates in the Active Pharmaceutical Ingredients (API) business segment. There are 2,63,157 Equity Share Warrantis outstanding, and 1,60,322 equity shares are still in the Unclaimed Suspense Account as of December 31, 2025. The company is undergoing a review by the Audit Committee and the Board of Directors. The company's financial results were prepared in accordance with Ind AS and other accounting principles generally accepted in India.

Everest Organics Limited has approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a sales turnover of Rs 5026.85 Lakhs, with domestic sales at Rs.3970.75 Lakhs and export sales at Rs. 1056.10 Lakhs. However, the company is operating at a higher production capacity without necessary approvals from the Telangana State Pollution Control Board (TSPCB), which could impact its going concern status. Additionally, the company has not recognized Rs.143 lakhs in interest expenses towards delayed payments to suppliers, nor has it determined the additional employee benefit obligation from the implementation of the New Labour Codes. The company's stock secretary and compliance officer, Shweta Singh, announced the results.